Every one of those 1 sits in a single category, pharma. Albany International is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention LEAP, all published on August 5, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about LEAP
Every one of those 1 sits in a single category, pharma. Albany International is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention LEAP, all published on August 5, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering LEAP. Shared-story counts are live from our verified record — not editorial picks.
Albany International’s Q2 performance, with adjusted EBITDA margin expanding to 17.6% and record Engineered Composites growth, underscores precision manufacturing at scale—capabilities directly relevant to bioprocessing equipment supply.